It is very uncertain whether summary of findings: Corticosteroids changes acute and late GI toxicity (grade 2+) compared with placebo (very low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 0.85 [0.62, 1.15]
1 study · 126 participants
Very low

Corticosteroids vs placebo

Diarrhoea (grade 2+) · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Corticosteroids vs placebo

QoL · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sucralfate vs placebo

Mean GI symptom scores · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sucralfate vs placebo

Acute and late GI toxicity (grade 2+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer

Summary of findings: Sucralfate showed no clear difference in acute and late GI toxicity (grade 2+) [acute = during RT; late = 6… compared with placebo (moderate certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 1.07 [0.83, 1.39]
1 study · 335 participants
Moderate

Sucralfate vs placebo

Diarrhoea (grade 2+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer

Summary of findings: Sucralfate may leads to lower diarrhoea (grade 2+) [during RT] compared with placebo (low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 0.81
4 studies · 284 participants
Low

Sucralfate vs placebo

QoL · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Amifostine vs no intervention

Mean GI symptom scores · People with urological, gynaecological or colorectal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: IMRT vs 3DCRT

Mean GI symptom scores (EORTC‐QLQPR25 scale; lower scores better) · People with urological (prostate) and gynaecological (cervical) cancer

Summary of findings: IMRT showed no clear difference in mean GI symptom scores (EORTC‐QLQPR25 scale; lower scores better) compared with 3DCRT (low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 181 participants
Low

Amifostine vs no intervention

Acute and late GI toxicity (grade 2+) · People with urological, gynaecological or colorectal cancer

Summary of findings: Amifostine may leads to lower acute and late GI toxicity (grade 2+) compared with no intervention (low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 0.25
3 studies · 278 participants
Low

Amifostine vs no intervention

Diarrhoea (grade 2+) · People with urological, gynaecological or colorectal cancer

It is very uncertain whether summary of findings: Amifostine changes diarrhoea (grade 2+) during treatment compared with no intervention (very low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 0.25 [0.06, 0.98]
1 study · 36 participants
Very low

Amifostine vs no intervention

QoL · People with urological, gynaecological or colorectal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Sodium butyrate vs placebo

Mean GI symptom scores · Men undergoing RT for prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Sodium butyrate vs placebo

Acute and late GI toxicity (grade 2+) · Men undergoing RT for prostate cancer

Summary of findings: Sodium butyrate showed no clear difference in acute and late GI toxicity (grade 2+) compared with placebo (moderate certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 0.91 [0.41, 1.98]
1 study · 79 participants
Moderate